ArticleJournal of clinical pathology2015

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.

Florian Eisner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.